CD45RB Antibody BRA-11 PE Conjugate | V2245PE NSJ Bioreagents

	Catalog No	Formulation	Size	Price (USD)
	V2245PE-100T	500 ul at 0.1 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide	100 Tests	559
Formulation

Catalog No

Formulation

Size

Price (USD)

V2245PE-100T

500 ul at 0.1 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide

100 Tests

559

Availability	1-3 business days
Species Reactivity	Human
Format	PE Conjugate
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	BRA-11
Purity	Protein G affinity chromatography
Gene ID	5788
Localization	Cell surface and cytoplasmic
Applications	Flow Cytometry : 5ul/test/10e6 cells in 100ul (or 5ul per 100ul of whole blood) Immunofluorescence : 1:50-1:100
Limitations	This CD45RB Antibody BRA-11 PE Conjugate is available for research use only.
	Review this product on BioCompare and get a $20 Amazon gift card

Description

CD45RB Antibody BRA-11 PE Conjugate detects CD45RB. CD45R, also designated CD45 and PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4), CD45RB (exon 5), CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out). The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45R functions as a phosphor-tyrosine phosphatase. antibody to CD45R is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms.

CD45RB is an alternatively spliced PTPRC isoform involved in lymphocyte differentiation and immune cell phenotyping; learn more about this target and related reagents on our CD45RB Antibody page.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD45RB Antibody BRA-11 PE Conjugate to be titered up or down for optimal performance.